CY1120026T1 - Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων - Google Patents

Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων

Info

Publication number
CY1120026T1
CY1120026T1 CY20181100293T CY181100293T CY1120026T1 CY 1120026 T1 CY1120026 T1 CY 1120026T1 CY 20181100293 T CY20181100293 T CY 20181100293T CY 181100293 T CY181100293 T CY 181100293T CY 1120026 T1 CY1120026 T1 CY 1120026T1
Authority
CY
Cyprus
Prior art keywords
treatment
krenolanibi
flt3
multiple disorders
flt3 mutants
Prior art date
Application number
CY20181100293T
Other languages
English (en)
Inventor
Vinay K. JAIN
Original Assignee
Arog Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120026(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals, Inc filed Critical Arog Pharmaceuticals, Inc
Publication of CY1120026T1 publication Critical patent/CY1120026T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη χρήση κρενολανίμπης σε μορφή φαρμακευτικώς αποδεκτού άλατος για τη θεραπευτική αγωγή των πολλαπλασιαστικών διαταραχών που έχουν μεταλλαχθεί με FLT3 οδηγούμενη από ιδιοσυστατικά ενεργοποιημένο μεταλλαγμένο FLT3 και με μια μέθοδο θεραπείας θερμόαιμων ζώων, κατά προτίμηση ανθρώπων, στους οποίους θεραπευτικά η αποτελεσματική δόση κρενολανίμπης χορηγείται σε ένα ζώο που πάσχει από την εν λόγω ασθένεια ή κατάσταση.
CY20181100293T 2013-01-07 2018-03-12 Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων CY1120026T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749695P 2013-01-07 2013-01-07
EP13869984.8A EP2941251B1 (en) 2013-01-07 2013-10-14 Crenolanib for treating flt3 mutated proliferative disorders

Publications (1)

Publication Number Publication Date
CY1120026T1 true CY1120026T1 (el) 2018-12-12

Family

ID=51061430

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100293T CY1120026T1 (el) 2013-01-07 2018-03-12 Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων

Country Status (31)

Country Link
US (7) US9101624B2 (el)
EP (1) EP2941251B1 (el)
JP (1) JP6288726B2 (el)
KR (1) KR101885952B1 (el)
CN (4) CN112138010A (el)
AP (1) AP2015008628A0 (el)
AU (1) AU2013371624B2 (el)
BR (1) BR112015016282A2 (el)
CA (1) CA2897445C (el)
CL (1) CL2015001923A1 (el)
CY (1) CY1120026T1 (el)
DK (1) DK2941251T3 (el)
EA (1) EA033910B1 (el)
ES (1) ES2667958T3 (el)
HK (1) HK1224211A1 (el)
HR (1) HRP20180478T1 (el)
HU (1) HUE038594T2 (el)
IL (1) IL239802B (el)
LT (1) LT2941251T (el)
MX (1) MX369137B (el)
NO (1) NO3019692T3 (el)
NZ (1) NZ710720A (el)
PE (1) PE20151525A1 (el)
PH (1) PH12015501531B1 (el)
PL (1) PL2941251T3 (el)
PT (1) PT2941251T (el)
RS (1) RS57076B1 (el)
SG (2) SG11201505327SA (el)
SI (1) SI2941251T1 (el)
WO (1) WO2014107209A2 (el)
ZA (1) ZA201505545B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN109069410B (zh) * 2016-02-26 2022-05-31 安吉奥斯医药品有限公司 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
JP7466308B2 (ja) 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
WO2022051429A1 (en) 2020-09-02 2022-03-10 Daniel Choi Systems and methods for augmented reality environments and tokens
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AU2363902A (en) * 2000-10-31 2002-05-15 Ciba Sc Holding Ag Crystalline forms of fluvastatin sodium
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
BRPI0411794A (pt) 2003-06-24 2006-08-08 Pfizer Prod Inc processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina
AU2006309171A1 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
AU2012345666A1 (en) * 2011-11-30 2014-06-19 Cedars-Sinai Medical Center Targeting microRNAs miR-409-5p, miR-379 and miR-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
KR20140040594A (ko) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 돌연변이체 c-kit의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Also Published As

Publication number Publication date
ES2667958T3 (es) 2018-05-16
EA201591290A3 (ru) 2016-07-29
AU2013371624A1 (en) 2015-08-20
NO3019692T3 (el) 2018-06-16
HUE038594T2 (hu) 2018-10-29
CN109966292A (zh) 2019-07-05
LT2941251T (lt) 2018-04-10
PH12015501531A1 (en) 2015-09-21
CL2015001923A1 (es) 2016-01-15
US9801870B2 (en) 2017-10-31
PH12015501531B1 (en) 2015-09-21
US20220409610A1 (en) 2022-12-29
HK1224211A1 (zh) 2017-08-18
EP2941251A2 (en) 2015-11-11
IL239802A0 (en) 2015-08-31
EA033910B1 (ru) 2019-12-09
BR112015016282A2 (pt) 2017-07-11
CA2897445C (en) 2019-04-30
JP6288726B2 (ja) 2018-03-07
US20140194464A1 (en) 2014-07-10
US10213423B2 (en) 2019-02-26
US9393240B2 (en) 2016-07-19
KR101885952B1 (ko) 2018-08-06
MX2015008777A (es) 2015-11-13
AP2015008628A0 (en) 2015-08-31
US20150238479A1 (en) 2015-08-27
PL2941251T3 (pl) 2018-07-31
NZ710720A (en) 2020-06-26
CN112138010A (zh) 2020-12-29
RS57076B1 (sr) 2018-06-29
EP2941251A4 (en) 2016-08-24
JP2016508148A (ja) 2016-03-17
DK2941251T3 (en) 2018-03-26
PE20151525A1 (es) 2015-10-23
US11458131B2 (en) 2022-10-04
AU2013371624B2 (en) 2018-02-08
CN110200970A (zh) 2019-09-06
US20190183879A1 (en) 2019-06-20
US20180015081A1 (en) 2018-01-18
SG11201505327SA (en) 2015-08-28
KR20150141930A (ko) 2015-12-21
HRP20180478T1 (hr) 2018-06-15
US9101624B2 (en) 2015-08-11
SG10201705611PA (en) 2017-08-30
WO2014107209A2 (en) 2014-07-10
SI2941251T1 (en) 2018-06-29
PT2941251T (pt) 2018-03-23
US20200390756A1 (en) 2020-12-17
US20160303109A1 (en) 2016-10-20
CA2897445A1 (en) 2014-07-10
EP2941251B1 (en) 2018-03-07
US11007188B2 (en) 2021-05-18
IL239802B (en) 2020-06-30
MX369137B (es) 2019-10-30
EA201591290A2 (ru) 2016-03-31
ZA201505545B (en) 2016-10-26
CN105555272A (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
CY1120026T1 (el) Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
EA201790398A1 (ru) Способы лечения заболевания печени
EA201692436A1 (ru) Медицинское применение
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
EA201691385A1 (ru) Комбинированная терапия рака
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CY1122220T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση των διαταραχων του κυκλου της ουριας
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα